Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4325910 | 0.75 | PIK3CD (0.70) | PIK3CDKDM4EALDH1A1 | |
| SCHEMBL26655296 | 0.73 | PIK3CD (0.52) | PIK3CDKDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL26655290 | 0.73 | PIK3CD (0.52) | PIK3CDKDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL932266 | 0.73 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL26655221 | 0.72 | PIK3CD (0.50) | PIK3CDKDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL26655215 | 0.72 | PIK3CD (0.50) | PIK3CDKDM4EALDH1A1DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL12080214 | 0.71 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL15140812 | 0.69 | PIK3CD (0.45) | PIK3CDKDM4EALDH1A1USP2ALOX15 | |
| SCHEMBL19209544 | 0.68 | PIK3CD (0.35) | PIK3CDKDM4EALDH1A1 | |
| SCHEMBL932864 | 0.67 | PIK3CD (0.33) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| EP-2448929-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001052-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | PIK3CD 3545/4885KDM4E 4517/4885ALDH1A1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.